Our community mourns the loss of Chad, who lived with RET+ lung cancer for 2.5 years. He loved deeply, lifted others and faced every setback with courage. His passing is a heartbreaking reminder: we still have a long way to go. Chad deserved more time. #LungCancerAwareness

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study - Journal of Thoracic Oncology #LCSM SmallCellSMASHERS jto.org/article/S1556-…

Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

Consensus statement from IASLC on molecular tumor boards in lung cancer (& oncology in general). Provides framework for implementation, report standardization, case selection, quality assessment. Performance metric: changes in management based on MTB. jto.org/article/S1556-…

Lung Cancer Europe - Major disparities in access to Molecular Tumour Boards Lung Cancer Europe IASLC oncodaily.com/insight/332230 #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

Available JTO & JTO CRR - the 2024 IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness. jto.org/article/S1556-…

Exploration of weight gain associated with TKIs for driver-positive NSCLC JTO & JTO CRR. Highest risk associated with lorlatinib (36%), alectinib (15%), crizotinib (5%), lowest with osimertinib and erlotinib. Important to monitor risk over time, management. jtocrr.org/article/S2666-…

⏰ For the incoming Hem-Onc Fellows Network Great summary of progress in lung cancer from the IASLC Comm Committee: 50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow’s Guide in the Clinic - Journal of Thoracic Oncology jto.org/article/S1556-… IASLC #lcsm Jarushka Naidoo

Brustugun et al. walk us through the surgical approaches, radiation approaches, systemic therapy, and more related to lung cancer in #Norway in this contribution to Lung Cancer Worldwide. Read now ➡️ bit.ly/44Qr5vS

Final analysis of DESTINY-Lung02 JTO & JTO CRR - dose finding study of trastuzumab deruxtecan (T-DXd, HER2 ADC) in HER2 mutant NSCLC comparing 5.4 vs 6.4mg/kg showed RR 50% vs 56%, PFS 10 vs 13m, G3+ AEs 40% vs 60%, ILD 15% vs 32%. Approved dose is 5.4mg/kg. jto.org/article/S1556-…

Are we ready for artificial intelligence in pathology? AIM-PD-L1 is an #AI model for digital PD-L1 scoring. Report JTO & JTO CRR compared digital to manual using NSCLC samples from IMpower 110 + 150 & showed high concordance and predicted clinical outcomes. jto.org/article/S1556-…

Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer buff.ly/4L4uRXA In the final analysis of the phase 2

Thanks for the interview and the attention to our study. AI is the future to efficient and cost effective lung cancer screening.

In this phase II trial evaluating the activity of #cabozantinib, Harada et al. demonstrated that this treatment could benefit pts w MET-altered lung cancers previously treated with type I MET TKIs. Read more: bit.ly/45quIt0

Finding the Right Match: Who Should Opt for Anti–CTLA-4 and Programmed Cell Death Protein-1 Combination Therapy? - Journal of Thoracic Oncology jto.org/article/S1556-…

As early-career oncologist, starting my second year of Faculty, I quickly learned that clinical skills are only part of the job. Here in this article, we reflect about the things that fellowship didn’tcover, and how to survive and thrive! Ibrahim Azar, MD connection.asco.org/do/eight-aspec…

A multidisciplinary panel from AABIP and IASLC convened to address Patient, Intervention, Comparison, and Outcome Qs pertaining to the safety & adequacy of comprehensive biomarker testing for frequently used intrathoracic biopsy techniques. Read more: bit.ly/4mx1pwh

The African Lung Cancer Community of Practice presents: 🌍Lung Cancer in Africa: Gaps and Role of a Community of Practice Alex A. Adjei Professor of Oncology and Pharmacology, chair of Cleveland Clinic Cancer Institute, and President Elect of the IASLC will be speaking at this

IASLC recommendations on Molecular Tumor Boards out in JTO & JTO CRR #PrecisionMedicine #MTB jto.org/article/S1556-…